Cartesian Therapeutics (RNAC) Long-Term Debt Repayments (2015 - 2023)

Cartesian Therapeutics (RNAC) has 5 years of Long-Term Debt Repayments data on file, last reported at $24.9 million in Q3 2023.

• Long-Term Debt Repayments for Q3 2023 came in at $24.9 million, changed N/A year-over-year; the trailing twelve-month figure through Dec 2024 was $24.9 million (changed 0.0% YoY), and the FY2023 annual result was $27.5 million, changed N/A from the prior year.
• Long-Term Debt Repayments rose to $24.9 million in Q3 2023 per RNAC's latest filing, from $15.1 million in the prior quarter.
• Over five years, Long-Term Debt Repayments peaked at $24.9 million in Q3 2023 and troughed at $700000.0 in Q3 2019.
• A 3-year average of $7.8 million and a median of $2.1 million in 2019 frame the typical range for Long-Term Debt Repayments.
• On a YoY basis, Long-Term Debt Repayments climbed as much as 2059.0% in 2020 and fell as far as 2059.0% in 2020.
• A 3-year view of Long-Term Debt Repayments shows it stood at $2.1 million in 2019, then jumped by 619.67% to $15.1 million in 2020, then surged by 64.57% to $24.9 million in 2023.
• Business Quant data shows RNAC's Long-Term Debt Repayments at $24.9 million in Q3 2023, $15.1 million in Q3 2020, and $2.1 million in Q2 2020.